This chapter outlines protocols that produce homogenous preparations of oligomeric and fibrillar amyloid -b peptide (Ab). While there are several isoforms of this peptide, the 42 amino acid form is the focus because of its genetic and pathological link to Alzheimer's disease (AD). Past decades of AD research highlight the dependence of Ab42 function on its structural assembly state. Biochemical, cellular and in vivo studies of Ab42 usually begin with purified peptide obtained by chemical synthesis or recombinant expression. The initial steps to solubilize and prepare these purified dry peptide stocks are critical to controlling the structural assembly of Ab. To develop homogenous Ab42 assemblies, we initially monomerize the peptide, erasing any "structural history" that could seed aggregation, by using a strong solvent. It is this starting material that has allowed us to define and optimize conditions that consistently produce homogenous solutions of soluble oligomeric and fibrillar Ab42 assemblies. These preparations have been developed and characterized by using atomic force microscopy (AFM) to identify the structurally discrete species formed by Ab42 under specific solution conditions. These preparations have been used extensively to demonstrate a variety of functional differences between oligomeric and fibrillar Ab42. We also present a protocol for fluorescently labeling oligomeric Ab42 that does not affect structure, as measured by AFM, or function, as measured by a cellular uptake assay. These reagents are critical experimental tools that allow for defining specific structure/function connections.
Introduction
Ab42, but not Ab40, forms oligomeric and fibrillar assemblies. 5 mM HFIP-treated Ab42 (a) or Ab40 (b) in DMSO was diluted to 100 mM in ice-cold F-12 culture media for oligomers, or 10 mM HCl for fibrils. Oligomer and fibril preparations were incubated for 24 h at 4°C and 37°C, respectively. Samples before (0 h) and after incubation (24 h) were mounted for AFM analysis at 10 mM. Representative 2 × 2 mm x-y, 10 nm total z-range AFM images. Inset images 200 × 200 nm x-y, 2 nm total z-range. Reprinted from Stine et al., JBC, 2003 , with permission from ASBMB. (c, d) Oligomeric Ab42, but not Ab40, reduces neuronal viability significantly more than fibrillar and unaggregated species. Unaggregated, oligomeric, and fibrillar preparations of Ab42 (c) or Ab40 (d) were incubated with N2A cells for 20 h. Oligomeric and fibrillar preparations of Ab were prepared as described above. For unaggregated peptide preparations, the 5 mM Ab in DMSO was diluted directly into cell culture media. The MTT assay was used as an indicator of cell viability. Graph represents the mean ± SEM for n ³ 10 from triplicate wells from at least three separate experiments using different Ab preparations. * Significant difference between Ab assemblies prepared in oligomers and fibrils conditions (p < 0.001). ** Significantdifference between unaggregated and both Ab assemblies prepared oligomers and fibrils conditions (p < 0.001). Reprinted The "toxic fibrils" formed by E22Q and E22G are significantly more toxic than WT oligomers. Changes to structural assembly states of mutant Ab42 observed by AFM (above) translate into changes in function as measured by cellular toxicity. N2A cells were treated for 20 h with 0.1 mM of WT Ab42 oligomers and fibrils, or mutant E22Q Ab42 or mutant E22G Ab42 assemblies from oligomer and fibril-forming conditions. MTT assay was used as an indicator of cell viability. methods, including neurotoxic activities, isolation techniques (primarily size exclusion chromatography (SEC)), size estimation such as by SDS or native PAGE, imaging techniques, and reactivity with various Ab conformation-specific antibodies. These multiple operative definitions of oligomeric Ab have resulted in a literature that is often difficult to interpret and almost impossible to compare. A rigorous approach is particularly important with Ab42, which aggregates faster and to a significantly greater extent than Ab40 and other shorter forms of the peptide (Fig. 1a, b ). AFM is particularly well suited to the analysis of amyloidogenic peptides and proteins that can assemble into a variety of structurally discrete species, specifically those like Ab. Polydispersity of morphologies and sizes often complicates or precludes the use of other biophysical techniques (such as NMR or light scattering methods), or is masked by solvent incompatibilities of the bulk solution (as for secondary structure detected by far-UV circular dichroism). Techniques based on separation by size (SDS-PAGE, Native PAGE and SEC) may lead to apparent multimers/sizes arising from technical artifacts due to matrix effects. AFM is one of the few techniques that provide direct, high-resolution, 3-dimensional morphological images of the broad range of structures present in a single scan without the need for chemical manipulation of the sample. Numerous studies have demonstrated several advantages of tapping mode AFM for Ab42 morphological characterization (3) (4) (5) (6) (7) (8) . We have used AFM for developing conditions that consistently produce homogenous preparations of oligomeric or fibrillar assemblies of Ab42 (9, 10) . We have used these preparations extensively to demonstrate significant functional differences between Ab42 oligomers and fibrils using a variety of experimental models (for example, Figs. 1c and 2b) (9, (11) (12) (13) (14) .
To directly assess the conformation-dependent differences among Ab assemblies, we have developed protocols for the preparation of homogeneous unaggregated, oligomeric, and fibrillar Ab42 (9, 10) ( Figs. 1 and 4 ). Because Ab42 is the isoform of the peptide most associated with AD, we chose to utilize it almost exclusively, with Ab40 used occasionally as a negative control ( Fig. 1b, d ). Using AFM to image Ab42, we remove preexisting aggregates and b-sheet secondary structure from Ab42 with a strong fluorinated alcohol, hexafluoroisopropanol (HFIP) ( Fig. 3 ), followed by solubilization of the now monomerized peptide in dimethylsulfoxide (DMSO). Starting with this monomeric peptide preparation, we further developed two aggregation protocols that consistently produce extensively oligomeric or fibrillar populations of Ab42 ( Fig. 1 ). For the "unaggregated" peptide preparation, the DMSOsolubilized peptide is diluted in the experimental solution (for example, culture media) and used immediately ( Fig. 1a , 0 h). To grow a "plaque in a dish," follow the fibril forming procedure, with the addition of salt at physiological concentrations ( Fig. 5a2 ). Note that AFM is an optimal method for determining the aggregation state of Ab42 as it is difficult to consistently identify Ab42 assemblies by Western analysis of SDS-PAGE ( Fig. 5 ) (15) . These distinct assemblies are derived from chemically identical and structurally homogeneous starting materials and are thus particularly well suited for comparative structure-function studies. We have demonstrated that in vitro, oligomeric Ab42 is ~10-fold more neurotoxic than the fibrillar (plaque-forming) assembly, and ~40-fold more toxic than the unaggregated peptide, with oligomeric Ab42-induced toxicity significant at 10 nM ( Fig. 1c ). Under Ab42 oligomer-and fibril-forming conditions, Ab40 remains predominantly as unassembled monomer ( Fig. 1b) and had significantly less effect on neuronal viability than preparations of Ab42 ( Fig. 1d ). We applied the aggregation protocols developed for wild type (WT) Ab42 to Ab42 with the Dutch (E22Q) or Arctic (E22G) mutations ( Fig. 2 ). Oligomeric preparations of the mutant peptides exhibited extensive protofibril and fibril formation, respectively, but were not consistently different from WT Ab42 in terms of inhibition of neuronal viability. However, fibrillar preparations of the mutants appeared larger in diameter and induced significantly more inhibition of neuronal viability than WT Ab42 fibril preparations. These data demonstrate that protocols developed to produce oligomeric and fibrillar Ab42 are useful in distinguishing the structural and functional differences between Ab42, Ab40, and Ab containing known genetic mutations.
Overview of Experimental Methods to Prepare and Characterize Defined Ab Assemblies (Unaggregated, Oligomers, Fibrils, and "Plaques-in-a-Dish")
As researchers become increasingly conscientious of utilizing structurally uniform, well-characterized Ab preparations, the same criteria need to be applied to fluorophore-labeled-Ab, prior to their widespread use as experimental tools. Numerous recent studies utilizing fluorophore-labeled Ab42 peptides demonstrate this need for defined methods of consistently preparing wellcharacterized fluorescent Ab assemblies (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . The fluorescent Ab42 reagents used to date are prepared from different sources of Ab assemblies, in many cases using Ab42 preparations that have not yet been structurally/morphologically characterized. Thus, structural comparisons between the unlabeled and labeled Ab assemblies are not possible. Establishing the specific structural form of the assemblies, by AFM and other methods, is necessary to be able to interpret and compare results from the various fluorescent Ab42 species. We present a method for preparing Alexa Fluor ® 488-labeled Ab oligomers, extending our structural and functional characterization to fluorophore-labeling of Ab42 oligomers. Structural characterization by AFM establishes a method for labeling uniform oligomeric assemblies that is comparable to unlabeled oligomeric Ab42 (Fig. 6a ). To compare function, we demonstrate that the uptake of labeled and unlabeled oligomeric Ab42 by neurons in vitro is also similar ( Fig. 6b ) (see Note 1). These well-characterized fluorophore-Ab42 oligomers are an exciting new reagent for use in a variety of studies designed to elucidate critical cellular and molecular mechanisms underlying the functions of this Ab42 assembly form in AD.
Preparation and Use of Fluorophore-Labeled Ab42 Assemblies
1. Chemical fume hood.
Synthetic human amyloid-b (1-42), (California Peptide
Research, Inc., Napa, CA) (see Note 2).
3. 1,1,1,3,3,3-Hexafluoro-2-Propanol. (Fig. 6b) Steps 1-7 need to be done in a fume hood.
Materials

Preparation of HFIP-Treated Ab Peptide Stocks
1. Prepare a 1 mM Ab solution by adding HFIP directly to the vial containing lyophilized powder through the rubber septum using a 2.5 mL glass Hamilton syringe with a Teflon plunger and sharp (not blunt-end) needle. For Ab42, add 2.217 mL to 10 mg peptide (see Note 6).
2. After the peptide is completely dissolved, pierce the septum with a syringe needle to release the vacuum (see Note 7).
3. Incubate the Ab -HFIP solution at room temperature (RT) for at least 30 min (see Note 8).
4. Decap the glass vial (pliers work well) and remove the rubber septum being careful not to allow the HFIP to come in contact with the septum. Have a rack of 0.5 mL or 1.7 mL microcentrifuge tubes ready.
5.
Using a positive-displacement repeating pipette, aliquot the solution into 10 mL (0.045 mg for Ab42) or 100 mL (0.45 mg for Ab42) aliquots in either 0.5 mL or 1.7 mL microcentrifuge tubes (see Note 9). Peptide Stocks (Figs. 3  and 4) 1. Start with a tube of freshly resuspended 5 mM Ab42 in DMSO at RT (see Note 15).
Methods
Preparation of HFIP-Treated Ab
2.
To this Ab aliquot, add ice-cold H 2 O to a final concentration of 100 mM Ab.
3. Vortex for 15 s and use immediately.
4. The expected AFM pattern for this preparation is shown in Fig. 1a, upper Fig. 1a , lower left panel.
The expected AFM pattern for this preparation is shown in
1. Start with a tube of freshly resuspended 5 mM Ab42 in DMSO at RT (see Note 15). Fig. 1a , lower right panel. 
To this
The expected AFM pattern for this preparation is shown in
Unaggregated Ab Preparation (see Note 14)
Oligomeric Ab Preparation
Fibrillar Ab Preparation
"Plaque in a Dish" Preparation
Fluorophore-Labeled Ab42
Oligomer Preparation (Fig. 6) according to the manufacturer instructions by adding 10% volume of 1 M NaHCO 3 .
5.
Dissolve the provided Alexa Fluor ® 488 TFP Ester into 10 mL ultrapure H 2 O immediately before adding to Ab oligomers. Use 8 mL dye for every 100 mL oligomer solution.
6. Incubate the labeling reaction for 15 min in the dark at RT.
7. In the meantime, prepare the spin columns by delivering 425 mL of the kit-provided Bio-Gel P-6 fine resin slurry into the provided spin column tubes. Prepare two spin columns for every 100 mL of oligomers. One minute before the end of the labeling incubation, centrifuge the spin columns at RT for 15 s at 16,000 × g per the manufacturer recommendations.
8. Add 55 mL of the crude labeling reaction to the top of the resin and centrifuge for 1 min at 16,000 × g to removed unincorporated fluorophore. The leftover crude reaction solution can be analyzed by gel.
9. Store the labeled product at 4°C protected from light. Avoid prolonged storage. 13. For representative example of expected results, see Fig. 5b .
Structural Characterization of Ab42 Preparations
Western Analysis by SDS-PAGE (see Note 16)
1. Fill a 10 mL syringe with ultrapure water and equip with a 0.02 mm filter. Discard the initial 1-2 mL syringe filter output. All subsequent steps use 0.02 mm-filtered water.
2. Prepare samples for spotting on mica by diluting to final concentrations of 10-30 mM in water.
3. Immediately before sample delivery, cleave away the top one to four layers of mica using adhesive tape to reveal a clean, flat, featureless surface.
4. For mica pre-treatment, add ~3 mL (enough to cover the surface) of 1 M HCl to mica for 30 s and rinse with two drops of water by letting water out of the syringe filter roll over the mica, held at a 45° angle on a magnetic surface (see Note 18).
5.
Immediately deliver sample onto mica and incubate for 3 min.
6. Rinse with three drops of water and blow dry with several gentle pulses of compressed air.
7. Incubate on benchtop for a few minutes to hours (covered to protect from dust) at RT until analysis (see Note 19) .
8. When AFM tip engages, optimize instrument parameters for each scan keeping contact force at a minimum, with scan rates between 1 and 2 Hz, drive amplitude between 20 and100 mV (depending on cantilever), and amplitude set point between 1.4 and 1.5 V.
9. Process data to remove vertical offset between scan lines by applying zero order flattening polynomials using NanoScope Software vs. 5.31R1.
10.
For representative examples of expected results, see Figs. 1-3, 5 and 6.
Cell Culture 1. Mouse neuroblastoma N2A cells are routinely grown in 100-mm tissue culture dishes containing 10 mL of complete growth medium, consisting of EMEM supplemented with 10% FBS and 1% penicillin/streptomycin. The cells are maintained in a humidified incubator at 37°C with a 5% CO 2 atmosphere.
2. Cells are split such that 0.5 × 10 6 cells were seeded in a new dish each time the cells reached 80-90% confluency. Briefly, when the cells reach this confluency (approximately once a week), the old growth medium is removed, and DPBS is used to wash cells. 1.5 mL of 0.05% Trypsin-EDTA solution is added to cells, and the dish is returned to the incubator for 2-5 min without disturbance. When cells are detached from the dish, 6 mL of the complete growth medium is added to halt the trypsinization of cells. Cells are collected in a sterile
Atomic Force Microscopy
Functional Characterization of Ab42 Preparations
3.8.1. Neurotoxicity/ Viability Assay (Figs. 1c, d  and 2b ) (see Note 5) 15 mL conical tube, and pelleted in a clinical centrifuge with the setting of 168 × g for 2 min. The supernatant is decanted and cells are resuspended in 6 mL of complete growth medium. The cell density in a 12 mL aliquot of this cell suspension is counted using a hemocytometer. Based on the counted cell density, an appropriate volume to deliver 0.5 × 10 6 cells is then added to a new 100 mm dish containing 10 mL of complete growth medium. The dishes are then placed back into the incubator.
Neurotoxicity Assay (see Note 5)
Day 1: Preparing Cells and Ab
3. Start fresh oligomeric or fibrillar Ab preparations so that they will be ready to use the next day.
4. Prepare a 96-well plate of N2A cells to be treated. N2A cells from a healthy growing dish are seeded at 5,000 cells/well on an all-white 96-well plate in complete growth medium. An accurate multichannel pipette is ideal to dispense cells. In experimental planning, calculate the minimal number of wells required. For example, within a 96-well plate, we typically perform five to six replicate treatments of the same dose of Ab assembly (e.g., 10 mM oligomers). Do not use corner wells in the plate as these wells do not have consistent luminescence values. Also include control wells containing medium without cells to measure the background luminescence of the wells. Cells are allowed to grow for 24 h before the start of treatments for the neurotoxicity assay. CellTiter-Glo ® reagent according to the manufacturer's instruction. Briefly, the reagent is thawed to reach RT and an equal volume (100 mL) of the reagent is added directly to the cells. The plate is then gently rotated in an orbital shaker for 10 min. The luminescence intensity is then measured in a luminescent plate reader.
8. To calculate the neurotoxicity, the data set is normalized to the vehicle-treated cells, which is set to 100% for viability, and the relative values of treated cells versus control cells is calculated accordingly. 1. Cellular uptake by neurons is reported only for oligomeric Ab42, as treatment with fibrillar Ab42 does not result in any detectable uptake in the model described (data not shown).
Neuronal Uptake
Assay (Fig. 6b) 2. In-house synthetic peptide or peptide from other vendors will also work, but it must be of very high purity and quality. The TFA salt (as opposed to the acetate or ammonium salt) is preferred. In-house material should be accurately weighed in clean glass vials with a HFIP-resistant closure.
3. Dry DMSO stocks can be made by transferring DMSO from a freshly opened ampule to a 1-2 mL glass vial with a DMSOresistant closure (such as Teflon -VWR, Cat. No. 66009-556). Store vials containing the dry DMSO in a dessicated glass jar in the dark at RT and discard after 2 weeks.
4. The glutamine supplementation is to match the composition of the Biosource phenol red-free F-12 media, which was described in the original oligomer protocol (10) but is no longer available.
5.
Originally, we used the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay (Roche Molecular Biochemicals) as a measure of neurotoxicity (9, 11) ( Figs. 1c, d  and 2b ). This method is based on the reduction of internalized MTT tetrazolium to a colored formazan compound by cellular redox potential. The formazan production is proportional to viable cells in culture. However, MTT reduction does not necessarily reflect cellular metabolic activity, as some Ab assemblies may also enhance exocytosis of MTT formazan (32) . This assay also requires relatively long staining and extraction times. Therefore, we now use the Promega CellTiter-Glo ® Luminescent Cell Viability Assay as a measure of in vitro neurotoxicity. This has resulted, as one would predict, in lower toxicity for comparable doses of Ab, and so higher doses of Ab42 are now required to achieve the same toxicity (12).
6. HFIP is corrosive and very volatile. Avoid contact and work in the fume hood; take care not to contact septum or other surfaces during solubilization. 10. The peptide should not be white or chunky. An even clear film is a strong indicator of good peptide quality.
11. These stocks should be stable for several months to years.
12. DMSO stock should be clear and colorless. Remember to use proper sterile technique. 13 . Do not store peptide as a DMSO stock for more than 1 h to avoid protofibril formation.
14. While the "unaggregated" prep is an ideal control for conformation, it is most useful in assays that require either a very low concentration of peptide (9) or a short incubation period (14) . Prolonged incubation at higher concentrations result in the uncontrolled aggregation of the peptide and unpredictable functional activity.
15. Do not keep 5 mM Ab stock on ice because the DMSO will solidify.
16. Western analysis by SDS-PAGE is not a method for assessing the conformation/assembly of Ab42 ( Fig. 5 ) (15) . However, it is useful for visualizing the relative amount of peptide for comparison between samples.
17.
Depending on the age of the electrode/power supply equipment, voltage, and current settings may affect the pattern and abundance of bands typically observed for Ab (monomer, dimer, trimer, and tetramer). We have found that power supply limits set at 90-100 V, 80 mA for 80-90 min for electrophoresis yield consistent results.
18. For Ab preparations in F-12, the HCl pretreatment of the mica improves consistent and uniform peptide adsorption to the mica. For Ab preparations in HCl or PBS, including the Alexa Fluor ® 488-labeled oligomers, no mica pretreatment is performed.
19. Dried sample disks can be stored in a helium-purged desiccator for several months.
